Observation of the curative effect of device-guided rehabilitation on respiratory function in stable patients with chronic obstructive pulmonary disease

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a serious lung disease for individuals in middle age and especially in old people. The study was aimed to observe the curative effect of device-guided rehabilitation on respiratory functions in stable COPD patients. Methods: Sixty-seven stable COPD patients were enrolled and assigned to the experiment group (n = 36) and the control group (n = 31). The conventional pulmonary rehabilitation treatments, including pursed lips breathing (PLB) and abdominal breathing training, were applied in the control group. Respiratory muscle training of the experiment group was performed using the respiratory endurance training device combined with traditional techniques. Both groups were assessed by 6-minute walk test (6MWT), COPD assessment test (CAT), body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index. Besides, the pulmonary function (FVC%, FEVl%) were measured at 6 months before and after treatment. Results: After treatment, the 6MWT, CAT, BODE index were significantly increased compared with pre-treatment in both groups ( P < .01), but not FVC% and FEVl%. Compared with the control group, the combination therapy in the experiment group could significantly improve the 6MWT ( P = .0094), CAT ( P = .0071) and BODE index ( P = .0064) as well as the changes of 6MWT ( P < .01), CAT ( P < .01), and BODE index ( P < .01) before and after treatment. Conclusions: The traditional respiratory training combined with device-guided pulmonary rehabilitation can improve the respiratory muscle function and athletic ability in stable COPD patients.

Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol

“…In the data published by Wang et al [ 34 ] to evaluate an intervention in stable COPD patients, a weighted common standard deviation of the CAT score of 5.69 was observed. Basing the sample calculation on these data, in a study of the superiority of montelukast compared to placebo with an intention-to-treat analysis, accepting an alpha risk of 0.05 and a beta risk under 0.2 in a two-tailed contrast, 142 individuals in the treatment group and 142 in the control group are needed to detect a difference of 2 units.…”

Double-blind Placebo-controlled Randomized Clinical Trial to Assess the Efficacy of Montelukast in Mild to Moderate Respiratory Symptoms of Patients With Long COVID E-SPERANZA COVID PROJECT Study Protocol

“…In the data published by Wang et al 34 to evaluate an intervention in stable COPD patients, a weighted common standard deviation of the CAT score of 5.69 was observed. Basing the sample calculation on these data, in a study of superiority of montelukast compared to placebo with an intention-to-treat analysis, accepting an alpha risk of 0.05 and a beta risk under 0.2 in a two-tailed contrast, 142 individuals in the treatment group and 142 in the control group are needed to detect a difference of 2 units.…”

Efficacy and safety of pulmonary rehabilitation training on lung function, quality of life, and T cell immune function in patients with stable chronic obstructive pulmonary disease: a randomized controlled trial

“…Chronic obstructive pulmonary disease (COPD) is a common disease of the elderly which seriously affects quality of life. It is likely the third most common cause of death in the world today (1), and has become a major public health problem worldwide. Clinically, COPD can be divided into acute exacerbation and stable phases.…”